Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting
- 1 July 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 176 (4) , 1028-1034
Abstract
Background National Institute for Health and Care Excellence guidance recommends assessment of psychological and social well‐being in people with psoriasis. Objectives To screen systematically for depression and anxiety in patients with psoriasis in routine clinical practice and to identify at‐risk groups for psychiatric morbidity. Methods Consecutive patients attending a single, tertiary centre over a 10‐month period were invited to complete the Patient Health Questionnaire Depression Scale (PHQ‐9), Generalized Anxiety Disorder Scale (GAD‐7) and Dermatology Life Quality Index (DLQI) as part of IMPARTS: Integrating Mental and Physical Healthcare: Research, Training and Services. Information on demographics, treatment and clinical disease severity was collated from electronic patient records. Regression models were used to identify at‐risk groups for psychiatric morbidity. Results Of 607 patients included (56·2% on biologics), 9·9% (95% confidence interval 7·5–12·3%) screened positive for major depressive disorder (MDD) and 13·1% (79/604) (95% confidence interval 10·4–15·8%) for generalized anxiety disorder (GAD; GAD‐7 score > 9). Suicidal ideation was reported in 35% of those with MDD; DLQI was < 10 in 38·3% and 45·6% cases of MDD and GAD, respectively. After adjusting for covariates, the risk of MDD or GAD was significantly higher in women and those with severe clinical disease, psoriatic arthritis and previous depression/anxiety. The risk of GAD was significantly increased with Asian ethnicity and use of topical treatments only. Conclusions Systematic screening for anxiety and depression identifies clinically important levels of depression and anxiety that may be missed using DLQI data alone. Women and those with severe disease, psoriatic arthritis and/or a prior history of psychiatric morbidity may be at particular risk.Keywords
Funding Information
- King's Health Partners
- National Institute for Health Research
- South London and Maudsley NHS Foundation Trust
- King's College London
- Guy's and St Thomas' NHS Foundation Trust
This publication has 27 references indexed in Scilit:
- Embedding integrated mental health assessment and management in general hospital settings: feasibility, acceptability and the prevalence of common mental disorderGeneral Hospital Psychiatry, 2014
- Does psychosocial stress play a role in the exacerbation of psoriasis?British Journal of Dermatology, 2013
- Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatmentsInternational Journal of Dermatology, 2011
- Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidanceBMJ, 2010
- Validity/Reliability of PHQ-9 and PHQ-2 Depression Scales Among Adults Living with HIV/AIDS in Western KenyaJournal of General Internal Medicine, 2008
- Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis CDigestive Diseases and Sciences, 2007
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- Performance of the PHQ-9 as a Screening Tool for Depression After StrokeStroke, 2005
- The PHQ-9Journal of General Internal Medicine, 2001
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994